Our results in these multi-species ARDS/VILI models demonstrate that the intravenous delivery of an eNAMPT-neutralizing antibody dramatically reduces multiple indices of lung injury severity including histological injury, BAL inflammatory indices (protein, neutrophils), plasma IL-6 levels and dynamic and static lung compliance. Here, IL6 is linked to acute respiratory distress syndrome.